Previous antiretroviral therapy for prevention of mother-to-child transmission of HIV does not hamper the initial response to PI-based multitherapy during subsequent pregnancy

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 2, 2011, Pages 126-135

  Briand, Nelly ^a   Mandelbrot, Laurent ^a,b,c   Blanche, Stéphane ^b,c   Tubiana, Roland ^d,e   Faye, Albert ^b,f   Dollfus, Catherine ^c   Le Chenadec, Jérôme ^a   Benhammou, Valérie ^a   Rouzioux, Christine ^b,c   Warszawski, Josiane ^a,c,g  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e INSERM   (France)

^f HÔPITAL ROBERT DEBRÉ   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

antiretroviral drugs; epidemiology; HAART; HIV; MTCT

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MONOTHERAPY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 79957932573     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318219a3fd     Document Type: Article

References (33)

1. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494. (Pubitemid 34456340)
2. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudinezidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA. 2001;285:2083-2093. (Pubitemid 32367825)
3. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:458-465.
4. Ioannidis JP, Abrams EJ, Ammann A, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads,1000 copies/ml. J Infect Dis. 2001;183:539-545. (Pubitemid 32147509)
5. Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS. 2008;22:289-299.
6. Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS. 2008;22:973-981. (Pubitemid 351652248)
7. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180. (Pubitemid 24331334)
8. Yeni P. Prise en charge médicale des personnes infectées par le VIH. Paris, France: Recommandations du groupe d'experts: Ministere de la Santé et des Solidarités; 2008.
9. Tuomala RE, Watts DH, Li D, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005;38:449-473. (Pubitemid 40381556)
10. de Ruiter A, Mercey D, Anderson J, et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med. 2008;9:452-502.
11. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Recommendations for a Public Health Approach. Geneva, Switzerland: 2010.
12. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351:229-240. (Pubitemid 38922817)
13. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007; 356:135-147. (Pubitemid 46089674)
14. Lockman S, Hughes MD, McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010;363: 1499-1509.
15. Coffie PA, Ekouevi DK, Chaix ML, et al. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis. 2008;46:611-621. (Pubitemid 351263504)
16. Chi BH, Sinkala M, Stringer EM, et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS. 2007;21:957-964. (Pubitemid 46684327)
17. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355: 2283-2296. (Pubitemid 44837777)
18. El-Sadr WM, Grund B, Neuhaus J, et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med. 2008;149:289-299.
19. Massad LS, Springer G, Jacobson L, et al. Pregnancy rates and predictors of conception, miscarriage and abortion in US women with HIV. AIDS. 2004;18:281-286. (Pubitemid 38253451)
20. van Benthem BH, de Vincenzi I, Delmas MC, et al. Pregnancies before and after HIV diagnosis in a european cohort of HIV-infected women. European Study on the Natural History of HIV Infection inWomen. AIDS. 2000;14:2171-2178.
21. Blair JM, Hanson DL, Jones JL, et al. Trends in pregnancy rates among women with human immunodeficiency virus. Obstet Gynecol. 2004;103: 663-668. (Pubitemid 40459025)
22. Keiser O, Gayet-Ageron A, Rudin C, et al. Antiretroviral treatment during pregnancy. AIDS. 2008;22:2323-2330.
23. Patel D, Cortina-Borja M, Thorne C, et al. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis. 2007;44:1647-1656. (Pubitemid 46871514)
24. Baroncelli S, Tamburrini E, Ravizza M, et al. Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes. AIDS Patient Care STDS. 2009;23:513-520.
25. Katz IT, Shapiro R, Li D, et al. Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study. J Acquir Immune Defic Syndr. 2010;54:27-34.
26. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350: 1023-1035. (Pubitemid 38269279)
27. de Mendoza C, Soriano V. Resistance to HIV protease inhibitors: mechanisms and clinical consequences. Curr Drug Metab. 2004;5: 321-328. (Pubitemid 38997446)
28. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344: 472-480. (Pubitemid 32164898)
29. Kozal M. Cross-resistance patterns among HIV protease inhibitors. AIDS Patient Care STDS. 2004;18:199-208. (Pubitemid 38552652)
30. Schnell T, Schmidt B, Moschik G, et al. Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples. AIDS. 2003;17:1258-1261. (Pubitemid 36667770)
31. Turner D, Schapiro JM, Brenner BG, et al. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. Antivir Ther. 2004;9:301-314. (Pubitemid 38878746)
32. Chaix ML, Descamps D, Wirden M, et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS. 2009;23:717-724.
33. Gingelmaier A, Eberle J, Kost BP, et al. Protease inhibitor-based antiretroviral prophylaxis during pregnancy and the development of drug resistance. Clin Infect Dis. 2010;50:890-894.